Duke University

  • Image

    Duke University

    Accelerating scientific discoveries, building healthy communities
  • Duke CTSI
    -
    Duke University

    KL2 awardees from Clinical and Translational Science Centers (CTSA) present virtual lectures as part of the CTSA Visiting Scholar Program. Duke University will host Ankit Shah, MD, Assistant Professor of Medicine, Division of Endocrinology, Diabetes and Metabolism, Rutgers University. Dr. Shah will present "Glycerol as a Direct and Indirect Contributor to Glucose Production." Despite current

  • Duke CTSI
    -
    Duke University

    KL2 awardees from Clinical and Translational Science Centers (CTSA) present virtual lectures as part of the CTSA Visiting Scholar Program. Duke University will host Rochelle Maxwell, MD, Pediatric Hematology/Oncology Fellow from Rockefeller University. Dr. Maxwell will present "Fanconi Anemia: Diverse Approaches to the Study of a Multi-Faceted Disease." Dr. Maxwell's presentation will describe

  • Duke University

    Learn what it takes to make your surveys as efficient as possible. Customize survey settings, manage survey participants, and stay up-to-date on survey progress and results

  • Duke University

    Learn how to build reports and view/export your project data/results in just a few steps!! You can also use the interactive Data Import tool is used to upload data from a comma-delimited (CSV) file, into your REDCap project. Instead of entering records one by one, you can use the import tool to upload multiple records at once.

  • Duke University

    This module describes the study-level documentation expected at Duke. It describes the regulatory binder, documents required for all studies, documents required for most studies, and documents that are required depending on the type of study. It discusses standard operating procedures. This module provides guidance for creating the binder or file, maintaining central files, and what should not be

  • Duke University

    This training provides information regarding the sponsor and investigator requirements for an IND or IDE as well as resources to ensure compliance with FDA regulations. There are two separate training modules that each focus on the requirements for the specific regulatory application that the sponsor or sponsor-investigator holds. Sponsors who hold an IND (for drugs and biologics) can complete the

  • Nephrotic Syndrome Rare Disease Clinical Research Network III (NEPTUNE)

    Focal and Segmental Glomerulosclerosis, Minimal Change Disease and Membranous Nephropathy, presenting as Nephrotic Syndrome (NS), are a group of rare renal diseases that may cause serious complications and end-stage kidney disease, generating significant individual, societal and economic burdens. The Nephrotic Syndrome Study Network (NEPTUNE) brings together physician scientists at 26 sites in the

  • Myasthenia Gravis Rare Disease Network (MGNet)

    Myasthenia gravis (MG) is an autoimmune disease that blocks the signal from nerve to muscle, producing weakness. The nature of the disease can range from isolated severe vision problems, like drooping eyelids or double vision, to profound general weakness leading to breathing muscle failure. Although the cause of MG is not known, the disease appears to vary based on the types of antibodies

  • Lysosomal Disease Network (LDN)

    Lysosomal disorders (LD) are a group of approximately 70 inherited metabolic conditions resulting from defects in lysosomal function; usually deficiency of a single enzyme required for the metabolism of lipids, glycoproteins, or mucopolysaccharides. Collectively, LD are not especially rare; estimates suggest that approximately 1 in 5,000 newborns will be affected with one identified LD

  • Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe)

    Amyotrophic lateral sclerosis (ALS) is a fatal disease that involves progressive death of motor nerves in the brain, brainstem and spinal cord. The disease is closely related to disorders such as primary lateral sclerosis, hereditary spastic paraplegia, progressive muscular atrophy and frontotemporal dementia. These diseases have shared genetic causes and underlying biology. They also have in

  • Brain Vascular Malformation Consortium (BVMC)

    The Brain Vascular Malformation Consortium (BVMC) focuses on three rare brain conditions: familial cerebral cavernous malformation (CCM), Sturge-Weber syndrome (SWS), and hereditary hemorrhagic telangiectasia (HHT). These disorders are poorly understood, are costly to manage, and can cause serious complications such as hemorrhages, seizures, and problems with spinal cord, nerve or brain function

  • Funding opportunity 2020

    The National Institutes of Health (NIH) awarded a research team at George Washington (GW), Yale, and Duke Universities $7.8 million to establish a rare disease network for Myasthenia Gravis.

  • A research project that received critical early funding from Duke CTSI is now ready to enter the $1.1 billion hernia market.
  • The Duke CTSA KL2 program was recently identified as one of the top program hubs by the Center for Leading Innovation and Collaboration (CLIC). The Duke KL2 program was a top performer in the KL2 education program – Underrepresented measure. The CLIC evaluates programs using a Common Metrics Initiative. In alignment with the CLIC’s current goals, the Duke KL2 program set a goal to increase the

  • Duke, UNC, and Wake Forest Coronavirus Collaboration
    -
    Wake Forest University Health Sciences
    The Wake Forest Clinical and Translational Science Institute (CTSI) in conjunction with Duke and UNC would like to invite postdoctoral scholars and early career faculty involved in research to attend Research Resilience in the Age of COVID-19: Insights from Sponsors and Investigators on Thursday, July 9 from 2:00 - 4:30 pm. This virtual conference brings together researchers from all three
  • Duke WebEx
    -
    Duke University

    Following the announcement of new FDA guidance on the conduct of clinical trials of medical products during the current COVID-19 pandemic, the Clinical Trials Transformation Initiative (CTTI) last week held a public call for experiences and insights from across clinical trials ecosystem. During this webinar, presenters will provide a summary of that aggregated feedback and offer best practices for

  • University Of North Carolina Chapel Hill
    Duke University
    Wake Forest University Health Sciences
    Medical University Of South Carolina
    University Of Miami School Of Medicine
    Virginia Commonwealth University
    ReGARDD provides academic researchers with the regulatory tools and resources necessary to successfully navigate the pathway from discovery to clinical implementation of new drugs, biologics and medical devices. Investigational New Drug or Biologic Investigational Device Exemption Educational Videos ReGARDD Sponsored Events Who We Are The Regulatory Guidance for Academic Research of Drugs and
  • Harnessing the power of data science
    Duke University

    The modern era of health analytics is built on data science. Data science merges computer science with statistics, creating new potential for extracting clinical insight from the exponentially increasing “big” data relevant to our patients’ health. Realizing this potential requires new capabilities and innovative technologies. For effective implementation in a healthcare setting, an Accelerator is

  • SCiTS_2020_Virtual
    -
    Duke University

    The 11th Annual International Science of Team Science Conference is June 1-4, 2020 at Duke University in Durham, NC! SciTS 2020 will bring together team science practitioners, scholars, and providers from a broad range of disciplines to share and advance the latest evidence-based methods in team collaboration and transdisciplinary science. Speakers and attendees will include investigators

  • Duke University

    This training provides information regarding the sponsor and investigator requirements for an IND or IDE as well as resources to ensure compliance with FDA regulations. There are two separate training modules that each focus on the requirements for the specific regulatory application that the sponsor or sponsor-investigator holds. Sponsors who hold an IND (for drugs and biologics) can complete the

  • Duke University
    Principles and Techniques for Developing and Delivering Effective Scientific Presentations This video series was created, designed, and presented by Kevin Weinfurt, PhD and Steve Grambow PhD. The series starts with a brief introduction and has four major sections: Section 1 — Telling Your Story: Principles and techniques for effective scientific storytelling. Section 2 — Creating Slides
  • Duke University
    The Regulatory Affairs Training Program is 6 weeks and consists of weekly discussions and lectures combined with independent study. There will be opportunities to review and discuss different types of regulatory submissions, including Investigational New Drug applications (INDs) and Investigational Device Exemptions (IDEs). Participants will also have the opportunity to attend an IRB meeting on